Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3 antibody) plus chemoradiotherapy in stage II/III esophageal/gastroesophageal junction (E/GEJ) carcinoma.
Authors
Ronan Joseph Kelly
Baylor University Medical Center, Dallas, TX
Ronan Joseph Kelly , Ali Hussainy Zaidi , Jenna VanLiere Canzoniero , Josephine Louella Feliciano , Russell K. Hales , K. Ranh Voong , Richard James Battafarano , Blair Anderson Jobe , Stephen Yang , Stephen Broderick , Jinny Suk Ha , Kellie Nicole Smith , Elizabeth D. Thompson , Fyza Shaikh , Eun Ji Shin , Ali Imran Amjad , Patrizia Guerrieri , Chen Hu , Valsamo Anagnostou , Vincent K. Lam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03044613
DOI
10.1200/JCO.2022.40.4_suppl.321
Abstract #
321
Poster Bd #
G4
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.
First Author: Anjali Rohatgi
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition.
First Author: Katherine M. Bever
Poster
2023 ASCO Annual Meeting
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.
First Author: Maria Gonzalez